Last Published:  03/26/21 03:33:57 PM (Central)
Responsible Element: Human Health Countermeasures (HHC)
Status: Open
The most common approach for mitigation of SMS has been administration of anti-motion sickness pharmacological agents (e.g., scopolamine  and promethazine with or without ephedrine). Intramuscular administration of promethazine has been shown to be in particular effective inflight but with more side effects on the ground. More efficient non-invasive administrations of the drugs have also been investigated such as nasal gels and sprays. Attempts to use non-pharmacological countermeasures have entailed pre-flight adaptation training, training to promote adaptability, biofeedback training, incremental head movements during and after reentry from spaceflight, post-flight balance rehabilitation, stroboscopic goggles, galvanic vestibular stimulation, vestibular stochastic resonance, etc.

Research approach:
Develop and validate countermeasures that mitigate G-transition motion sickness while enabling crewmembers to continue to perform critical mission tasks. These countermeasures may be validated in ground-based analogs that provide transient disruption in vestibular function, acute vestibular clinical analogs or using ISS as a spaceflight analog. New pharmacological approaches are needed to improve efficacy in mitigating motion sickness while minimizing side effects to maintain crew performance. The addition of non-pharmacological countermeasures is desired to reduce reliance on medication and maintain crew performance. The appropriateness of the countermeasure is expected to vary based on the timeframe implemented, e.g. suppressing vestibular hypersensivity shortly after G-transitions versus enhancing vestibular function during later stages of recovery. Feasibility may also depend on design reference mission, e.g., planetary versus water landings.
Target for Closure
Provide and verify a set of countermeasures to mitigate motion sickness and spatial disorientation decrements during and following G-transitions. Characterize how these prevention or treatments reduce the risk of injury or enable crewmembers to perform critical operational tasks, e.g., document neurocognitive side effects and perform functional tasks involving egress. Results/deliverables: Ground validated motion sickness countermeasures.
Risk Risk of Impaired Control of Spacecraft/Associated Systems and Decreased Mobility Due to Vestibular/Sensorimotor Alterations Associated with Spaceflight
You are here! Gap SM-203: Develop and test SMS countermeasures.

No Documentation Available